JPWO2022002940A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022002940A5 JPWO2022002940A5 JP2023500008A JP2023500008A JPWO2022002940A5 JP WO2022002940 A5 JPWO2022002940 A5 JP WO2022002940A5 JP 2023500008 A JP2023500008 A JP 2023500008A JP 2023500008 A JP2023500008 A JP 2023500008A JP WO2022002940 A5 JPWO2022002940 A5 JP WO2022002940A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- subject
- drug conjugate
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 123
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 123
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 35
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 35
- 201000010881 cervical cancer Diseases 0.000 claims description 35
- 102000002262 Thromboplastin Human genes 0.000 claims description 31
- 108010000499 Thromboplastin Proteins 0.000 claims description 31
- 229960001592 paclitaxel Drugs 0.000 claims description 31
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 31
- 229930012538 Paclitaxel Natural products 0.000 claims description 29
- 230000004083 survival effect Effects 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 230000002411 adverse Effects 0.000 claims description 19
- 229960000106 biosimilars Drugs 0.000 claims description 12
- 229950004269 tisotumab vedotin Drugs 0.000 claims description 12
- 229960000397 bevacizumab Drugs 0.000 claims description 11
- 229960004562 carboplatin Drugs 0.000 claims description 11
- 190000008236 carboplatin Chemical compound 0.000 claims description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 11
- 229960004316 cisplatin Drugs 0.000 claims description 11
- 229960000303 topotecan Drugs 0.000 claims description 11
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 11
- 230000000306 recurrent effect Effects 0.000 claims description 8
- 238000009121 systemic therapy Methods 0.000 claims description 7
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 206010038111 Recurrent cancer Diseases 0.000 claims description 4
- 239000003889 eye drop Substances 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000019025 Hypokalemia Diseases 0.000 claims description 2
- 206010021036 Hyponatraemia Diseases 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229940115080 doxil Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000001780 epistaxis Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960002014 ixabepilone Drugs 0.000 claims description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 208000024896 potassium deficiency disease Diseases 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 2
- 229960002066 vinorelbine Drugs 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 238000009109 curative therapy Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 94
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045448P | 2020-06-29 | 2020-06-29 | |
| US63/045,448 | 2020-06-29 | ||
| US202063094571P | 2020-10-21 | 2020-10-21 | |
| US63/094,571 | 2020-10-21 | ||
| PCT/EP2021/067855 WO2022002940A1 (en) | 2020-06-29 | 2021-06-29 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533937A JP2023533937A (ja) | 2023-08-07 |
| JPWO2022002940A5 true JPWO2022002940A5 (pt) | 2024-06-19 |
Family
ID=76744843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500008A Pending JP2023533937A (ja) | 2020-06-29 | 2021-06-29 | 抗組織因子抗体－薬物コンジュゲートおよびがん治療におけるその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230263902A1 (pt) |
| EP (1) | EP4171652A1 (pt) |
| JP (1) | JP2023533937A (pt) |
| KR (1) | KR20230028492A (pt) |
| CN (1) | CN116322787A (pt) |
| AU (1) | AU2021299947A1 (pt) |
| BR (1) | BR112022025105A2 (pt) |
| CA (1) | CA3183898A1 (pt) |
| IL (1) | IL299334A (pt) |
| MX (1) | MX2022015375A (pt) |
| TW (1) | TW202216210A (pt) |
| WO (1) | WO2022002940A1 (pt) |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5879936A (en) | 1988-04-18 | 1999-03-09 | Aluguisse Holding A.G. | Recombinant DNA methods, vectors and host cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5891693A (en) | 1990-01-25 | 1999-04-06 | Alusuisse Holdings A.G. | Recombinant DNA methods vectors and host cells |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | ＨＥＲ２／ｎｅｕに対するヒトモノクローナル抗体 |
| EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
| PT1354034E (pt) | 2000-11-30 | 2008-02-28 | Medarex Inc | Roedores transgénicos transcromossómicos para produção de anticorpos humanos |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| JP5020636B2 (ja) | 2003-11-06 | 2012-09-05 | シアトル ジェネティックス， インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
| RU2486199C2 (ru) | 2003-12-10 | 2013-06-27 | Медарекс, Инк. | Выделенное антитело против ip-10, иммуноконъюгат и биспецифическая молекула на его основе, их композиции, способ лечения (варианты), кодирующая молекула нуклеиновой кислоты, соответствующий экспрессионный вектор, клетка-хозяин и гибридома |
| JP5064037B2 (ja) | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
| EP1725586B1 (en) | 2004-03-02 | 2015-01-14 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| EP1817336B1 (en) | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| SI3248613T1 (sl) | 2005-07-18 | 2022-04-29 | Seagen Inc. | Konjugati beta-glukuronidni linker-zdravilo |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| NZ604718A (en) | 2010-06-15 | 2015-01-30 | Genmab As | Human antibody drug conjugates against tissue factor |
| MX2016006488A (es) | 2013-11-21 | 2016-08-03 | Genmab As | Formulacion liofilizada de conjugado de anticuerpo-farmaco. |
| JP2021501776A (ja) * | 2017-11-02 | 2021-01-21 | ゲンマブ エー／エス | 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 |
-
2021
- 2021-06-29 TW TW110123815A patent/TW202216210A/zh unknown
- 2021-06-29 CN CN202180053328.8A patent/CN116322787A/zh active Pending
- 2021-06-29 MX MX2022015375A patent/MX2022015375A/es unknown
- 2021-06-29 IL IL299334A patent/IL299334A/en unknown
- 2021-06-29 JP JP2023500008A patent/JP2023533937A/ja active Pending
- 2021-06-29 EP EP21737082.4A patent/EP4171652A1/en active Pending
- 2021-06-29 KR KR1020237002734A patent/KR20230028492A/ko unknown
- 2021-06-29 AU AU2021299947A patent/AU2021299947A1/en active Pending
- 2021-06-29 WO PCT/EP2021/067855 patent/WO2022002940A1/en unknown
- 2021-06-29 BR BR112022025105A patent/BR112022025105A2/pt unknown
- 2021-06-29 CA CA3183898A patent/CA3183898A1/en active Pending
- 2021-06-29 US US18/010,783 patent/US20230263902A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoneshima et al. | Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC | |
| Lee et al. | An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3021) | |
| Gazzah et al. | Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study | |
| ten Tije et al. | Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial | |
| US20210015787A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| Iwase et al. | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| Herrero et al. | Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study | |
| EP3969001A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer | |
| Kosmas et al. | Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours | |
| US11419862B2 (en) | Quinoline derivative for treatment of nasopharyngeal carcinoma | |
| JPWO2022002940A5 (pt) | ||
| Seki et al. | Feasibility study of nanoparticle albumin-bound-paclitaxel and S-1 followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with operable breast cancer: A prospective study | |
| Ch’ang et al. | Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer | |
| Zhu et al. | Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma | |
| Bloom et al. | Ocular complications with the use of radium-223: a case series | |
| Kallab et al. | A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer | |
| Nam et al. | Safety and tolerability of weekly genexol-pm, a cremophor-free polymeric micelle formulation of paclitaxel, with carboplatin in gynecologic cancer: a phase i study | |
| Inoue et al. | Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer | |
| CN107456456A (zh) | 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途 | |
| Nishikawa et al. | The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients | |
| Mamounas et al. | Combined anthracycline-taxane regimens in the adjuvant setting | |
| LeCaer et al. | Multicenter Phase II Trial of Carboplatin/Vinorelbine in Elderly Patients with Advanced Non–Small-Cell Lung Cancer–Efficacy and Impact on Quality of Life: Groupe Français de Pneumo-Cancérologie Study 9902 | |
| Soda et al. | Phase I Trial of Pemetrexed in Combination with Carboplatin Followed by Pemetrexed Maintenance Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer |